Vor Biopharma Inc. (VOR)

NMS – Цена в реальном времени. Валюта: USD

16.10

+1.17 (7.84%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

15.27

-0.83 (-5.16%)

После закрытия: Jun 26, 2026, 7:40 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Vor Biopharma Inc. (VOR)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Vor Biopharma Inc. (VOR)

Telitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in China

Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference

Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine

Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade

Видео

No Data

Пресс-релизы

Telitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in China

Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine

Search stocks

Vor Biopharma Inc. (VOR)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Vor Biopharma Inc. (VOR)

Telitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in China

Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference

Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine

Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade

Видео

No Data

Пресс-релизы

Telitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in China

Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine